Colorectal Surgery Review

Defines the role of the "Surgical IBDologist" and bowel-sparing strategies. We break down strictureplasty techniques (Heineke-Mikulicz, Finney, Michelassi) and introduce the Kono-S anastomosis, which shows promising data for reducing recurrence. The episode addresses the controversy of wide mesenteric excision (Coffey study), the management of the "victim sigmoid" in ileosigmoid fistulas, and the critical distinction between fibrotic vs. inflammatory strictures on imaging.

Focused on perianal pathology, this episode establishes MRI as the gold standard for mapping complex fistulas (Likelihood Ratio 22.7). We review Heller's Rule for fistula risk and the four core principles of management, prioritizing sepsis control over repair. The discussion includes the contraindication of steroids in perianal disease, the use of loose setons, and emerging therapies like adipose-derived stem cells, while challenging the utility of traditional cutting repairs like LIFT in this population.

A rigorous review of Crohn's pharmacotherapy, highlighting the "Do Nots": antibiotics and 5-ASAs have limited to no role in luminal disease. We explore the "Treat to Target" approach and the decision tree for Therapeutic Drug Monitoring (TDM) when patients lose response. The episode also covers perioperative washout periods for biologics and the landmark LIR!C trial, which validates early resection as a primary alternative to medical therapy for limited ileitis.

Tailored for surgeons, this review covers when medical therapy has failed. We discuss the shift from symptom control to "mucosal healing" and the specific risks of 5-ASAs and thiopurines (TPMT testing). The episode details the management of Acute Severe UC (ASUC) using modified Truelove and Witts criteria, the timeline for "salvage therapy" (Infliximab vs. Cyclosporine), and the danger of "sequential salvage" which delays necessary colectomy.

Updates on the diagnostic workup for IBD, emphasizing the "immigration effect" as proof of environmental triggers. We clarify phenotypic mimics to avoid surgical disasters, such as distinguishing "backwash ileitis" and the "cecal patch" from Crohn's disease. The session covers the crucial Rutgeerts score for post-op recurrence (treating an i2 score), the utility of fecal calprotectin (<50 to rule out inflammation), and the new terminology replacing DALM: visible vs. invisible dysplasia.

A high-yield look at the molecular and environmental drivers of IBD, moving beyond simple autoimmune definitions. We explore the "four pillars" of pathogenesis, including the NOD2 gene's role in autophagy defects and the specific dysbiosis signatures (low Firmicutes, high Proteobacteria). The episode explains the global rise of IBD in newly industrialized nations and how understanding specific pathways, like the IL-23/Th17 axis, dictates modern biologic therapy and surgical timing.

This episode dismantles the historical dogma of mandatory fecal diversion, advocating for primary repair even in destructive colon injuries based on the Stone and AAST trials. We review the obsolete "4Ds" of rectal trauma, explaining why distal washout and presacral drains are now considered harmful risk factors. The discussion includes damage control principles (the lethal triad), the safety of anastomosis in high-risk patients, and the "End-Loop" colostomy technique.

A targeted review for the colorectal surgeon on managing Deep Infiltrating Endometriosis (DIE). The episode highlights the diagnostic delay (7–12 years) and the critical "negative sliding sign" on physical exam. We navigate the surgical decision tree—shave vs. disc excision vs. segmental resection—based on the size and depth of the lesion. Also covered is the "systemic disease" theory suggesting immune dysfunction, and why colonoscopy often fails to diagnose this "outside-in" pathology.

Essential knowledge for the management of Lower GI Hemorrhage (LGIB), a common and high-stakes emergency. Initial management requires recognizing if the source is likely upper GI (hematochezia plus instability) and strict transfusion targets (Hgb 7; Hgb 9 for cardiovascular risk patients). Risk stratification hinges on the Shock Index and the Oakland Score, where a score of eight or less predicts safe outpatient discharge. The diagnostic pathway utilizes CTA for low-flow bleeds and angiography for high-flow bleeds. For endoscopic intervention, clips are strictly preferred over thermal energy for diverticular bleeding due to perforation risk. Surgical intervention is the last resort, emphasizing the need for India Ink tattooing to localize the source, allowing for a targeted segmental colectomy rather than a high-morbidity blind subtotal colectomy.

A crucial review of Large Bowel Obstruction (LBO), emphasizing the foundational physiology of the closed-loop obstruction caused by a competent ileocecal valve, leading to imminent perforation risk dictated by the Law of Laplace (highest risk at the cecum). CT is the definitive modality for locating the transition point. Management of malignant LBO is highly sensitive; emergency right colectomy is associated with 10% mortality and 14% leak rate. While Subtotal Colectomy (STC) avoids a high-risk anastomosis, it carries a high functional cost (41% of patients report high bowel frequency). For Sigmoid Volvulus, initial endoscopic detorsion must be followed by mandatory elective resection due to high recurrence risk (45-70%). Acute Colonic Pseudo-Obstruction (ACPO) is managed with Neostigmine, a highly effective agent that requires continuous cardiac monitoring due to the risk of severe bradycardia.